Pay in 4 interest-free payments of $6.61 Learn more
Ships within 48 hours · Estimated delivery Aug 24 - Aug 29
It states that anti-obesity medications that receive FDA approval for an additional condition other than weight-management alone, can be considered a Part D drug for that specific use
In the Surmount-OSA clinical trial, patients lost an average of 15% of their body weight using tirzepatide, which led to approximately 50% improvement in sleep apnea severity
For people with type 2 diabetes, tirzepatide has demonstrated superior A1C reduction compared to GLP-1-only medications
The cost and coverage environment for the different brand names can be complex
Who should avoid it: anyone with melanoma risk factors
US$ 28.85
:max_bytes(150000):strip_icc()/Health-GettyImages-2236560849-a1934f1e4c004a19835cb508d021388b.jpg)
US$ 23.91
US$ 25.23
